Annual report
4544.TEDINET S100QZI9
Period2022-04-01 → 2023-03-31
Filed2023-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥223.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥188.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥181.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥23.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥50.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥25.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.9bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥41.3bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥516m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.4bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥252.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥219.4bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥201.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥115.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥103.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥113.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥36.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥33.7bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥35.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥21.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥32.0bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.38 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.06 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.94 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥306.32 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.91 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,635.26 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,463.33 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,020.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,809.18 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,980.27 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 23.2% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,437 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,444 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,897 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,968 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,957 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥15.0bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥40.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥9.3bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥13.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥8.7bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥12.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.2bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.8bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥12.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥115m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥27.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥182.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥173.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥167.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥161.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥117.1bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥119.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥114.9bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥63.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.5bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥66.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥47.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥37.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥38.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥225.98 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.08 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥485.53 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.61 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥225.97 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥103.05 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥485.42 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.6 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥125 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥125 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥144 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,108.11 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,032.83 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,058.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,171.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥822.27 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 21.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 48.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 57,471,867 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,446,657 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,416,407 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,387,861 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,361,385 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 392 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 330 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 322 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 340 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥23.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥4.5bn |
| Clinical Lab Testing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥12.0bn |
| Clinical Lab Testing Businessreportable segment | employees | at 2023-03-31 | 2176 pure |
| Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥163.4bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥163.1bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥293m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2023-03-31 | ¥131.1bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥279m |
| In Vitro Diagnostics Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.4bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.2bn |
| In Vitro Diagnostics Businessreportable segment | employees | at 2023-03-31 | 1048 pure |
| In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥77.7bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥70.1bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.6bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2023-03-31 | ¥129.2bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.5bn |
| Sterilization And Related Servicesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | employees | at 2023-03-31 | 1029 pure |
| Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥17m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2023-03-31 | ¥13.8bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥21.4bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥17.8bn |
| —segment total | employees | at 2023-03-31 | 4253 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥268.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥260.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| —segment total | segment assets | at 2023-03-31 | ¥274.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥27.9bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥10.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥10.2bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥25.8bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Clinical Lab Testing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥23.1bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥8.5bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥180.2bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥179.9bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥306m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2022-03-31 | ¥142.1bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.6bn |
| In Vitro Diagnostics Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥10.8bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥74.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥64.3bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9.8bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2022-03-31 | ¥105.6bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥26.7bn |
| Sterilization And Related Servicesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥28.7bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥28.7bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥22m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2022-03-31 | ¥13.1bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥36.6bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥13.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥283.1bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥272.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10.2bn |
| —segment total | segment assets | at 2022-03-31 | ¥260.8bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,747
| Item | Context | Value | Unit |
|---|---|---|---|
| Goodwill | Prior1YearInstant | 201000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 16000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 159000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 27000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 203000000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 128000000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 4198000000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 126000000 | JPY |
| Goodwill | CurrentYearInstant_UnallocatedAmountsAndEliminationMember | － | JPY |
| Goodwill | CurrentYearInstant | 4453000000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 38340000000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 37446000000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 449000000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 411000000 | JPY |
| Prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 456000000 | JPY |
| Prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 461000000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | Prior1YearInstant_NonConsolidatedMember | 725000000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 22506000000 | JPY |
| Accounts receivable other | Prior1YearInstant_NonConsolidatedMember | 11866000000 | JPY |
| Accounts receivable other | CurrentYearInstant_NonConsolidatedMember | 9385000000 | JPY |
| Other ca | Prior1YearInstant_NonConsolidatedMember | 346000000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 427000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant_NonConsolidatedMember | -206000000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant_NonConsolidatedMember | -956000000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 51979000000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 69683000000 | JPY |
| Buildings net | Prior1YearInstant_NonConsolidatedMember | 1546000000 | JPY |
| Buildings net | CurrentYearInstant_NonConsolidatedMember | 853000000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant_NonConsolidatedMember | 978000000 | JPY |
| Tools furniture and fixtures net | CurrentYearInstant_NonConsolidatedMember | 882000000 | JPY |
| Land | Prior1YearInstant_NonConsolidatedMember | 1706000000 | JPY |
| Land | CurrentYearInstant_NonConsolidatedMember | 1706000000 | JPY |
| Lease assets ppe | Prior1YearInstant_NonConsolidatedMember | 412000000 | JPY |
| Lease assets ppe | CurrentYearInstant_NonConsolidatedMember | 356000000 | JPY |
| Construction in progress | Prior1YearInstant_NonConsolidatedMember | 99000000 | JPY |
| Construction in progress | CurrentYearInstant_NonConsolidatedMember | 120000000 | JPY |
| Property plant and equipment | Prior1YearInstant_NonConsolidatedMember | 4743000000 | JPY |
| Property plant and equipment | CurrentYearInstant_NonConsolidatedMember | 3919000000 | JPY |
| Software | Prior1YearInstant_NonConsolidatedMember | 1082000000 | JPY |
| Software | CurrentYearInstant_NonConsolidatedMember | 872000000 | JPY |
| Lease assets ia | Prior1YearInstant_NonConsolidatedMember | 153000000 | JPY |
| Lease assets ia | CurrentYearInstant_NonConsolidatedMember | 107000000 | JPY |
| Other ia | Prior1YearInstant_NonConsolidatedMember | 191000000 | JPY |
| Other ia | CurrentYearInstant_NonConsolidatedMember | 89000000 | JPY |
| Intangible assets | Prior1YearInstant_NonConsolidatedMember | 1427000000 | JPY |
| Intangible assets | CurrentYearInstant_NonConsolidatedMember | 1070000000 | JPY |
| Investment securities | Prior1YearInstant_NonConsolidatedMember | 1218000000 | JPY |
| Investment securities | CurrentYearInstant_NonConsolidatedMember | 504000000 | JPY |
| Stocks of subsidiaries and affiliates | Prior1YearInstant_NonConsolidatedMember | 48107000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |